Eupraxia Pharmaceuticals Inc
NASDAQ:EPRX
Cash Flow Statement
Cash Flow Statement
Eupraxia Pharmaceuticals Inc
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||
| Net Income |
(5)
|
(4)
|
(11)
|
(16)
|
(20)
|
(23)
|
(18)
|
(19)
|
(19)
|
(24)
|
(25)
|
(27)
|
(34)
|
(29)
|
(30)
|
(28)
|
(23)
|
(26)
|
(26)
|
(29)
|
(29)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
2
|
3
|
3
|
3
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
2
|
2
|
3
|
5
|
4
|
4
|
|
| Other Non-Cash Items |
2
|
2
|
7
|
8
|
9
|
9
|
3
|
3
|
2
|
3
|
3
|
3
|
6
|
3
|
2
|
2
|
(1)
|
2
|
4
|
5
|
4
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
1
|
2
|
(2)
|
(2)
|
(0)
|
(0)
|
1
|
3
|
(1)
|
2
|
1
|
0
|
2
|
5
|
7
|
3
|
(2)
|
(7)
|
(8)
|
(6)
|
0
|
|
| Cash from Operating Activities |
(1)
N/A
|
(0)
+70%
|
(5)
-1 218%
|
(10)
-80%
|
(11)
-18%
|
(15)
-31%
|
(14)
+3%
|
(14)
+4%
|
(17)
-25%
|
(19)
-10%
|
(21)
-12%
|
(23)
-9%
|
(25)
-9%
|
(21)
+17%
|
(21)
+1%
|
(23)
-10%
|
(25)
-10%
|
(30)
-20%
|
(30)
+0%
|
(30)
-2%
|
(25)
+19%
|
|
| Investing Cash Flow | ||||||||||||||||||||||
| Capital Expenditures |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
(0)
|
0
|
(5)
|
(5)
|
(5)
|
(14)
|
(9)
|
(18)
|
(18)
|
9
|
0
|
18
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing Activities |
(0)
N/A
|
0
N/A
|
(5)
N/A
|
(5)
N/A
|
(5)
-8%
|
(14)
-166%
|
(9)
+35%
|
(19)
-97%
|
(18)
+2%
|
9
N/A
|
9
N/A
|
18
+105%
|
18
+0%
|
(0)
N/A
|
(0)
+4%
|
(0)
+39%
|
(0)
-76%
|
(0)
-1%
|
(0)
-216%
|
(0)
-77%
|
(0)
-4%
|
|
| Financing Cash Flow | ||||||||||||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
0
|
38
|
0
|
51
|
51
|
14
|
14
|
7
|
29
|
21
|
44
|
38
|
16
|
55
|
32
|
32
|
106
|
|
| Net Issuance of Debt |
1
|
(0)
|
3
|
12
|
12
|
12
|
10
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(5)
|
(9)
|
(9)
|
0
|
(5)
|
0
|
|
| Other |
0
|
(0)
|
38
|
38
|
38
|
0
|
(38)
|
(38)
|
(38)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
1
N/A
|
(1)
N/A
|
41
N/A
|
50
+23%
|
50
0%
|
50
+0%
|
9
-81%
|
13
+42%
|
13
-3%
|
14
+4%
|
14
+2%
|
7
-52%
|
29
+336%
|
21
-26%
|
44
+108%
|
33
-24%
|
7
-80%
|
46
+578%
|
23
-50%
|
28
+21%
|
106
+282%
|
|
| Change in Cash | ||||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
1
|
0
|
(0)
|
1
|
0
|
0
|
0
|
(2)
|
(1)
|
(0)
|
(1)
|
|
| Net Change in Cash |
(1)
N/A
|
(1)
-29%
|
31
N/A
|
35
+16%
|
33
-6%
|
21
-38%
|
(14)
N/A
|
(19)
-31%
|
(22)
-17%
|
4
N/A
|
2
-49%
|
2
-15%
|
21
+1 174%
|
1
-95%
|
24
+2 081%
|
11
-55%
|
(18)
N/A
|
14
N/A
|
(8)
N/A
|
(4)
+58%
|
80
N/A
|
|
| Free Cash Flow | ||||||||||||||||||||||
| Free Cash Flow |
(1)
N/A
|
(0)
+70%
|
(5)
-1 218%
|
(10)
-81%
|
(12)
-22%
|
(15)
-30%
|
(15)
+3%
|
(14)
+2%
|
(17)
-21%
|
(19)
-10%
|
(21)
-12%
|
(23)
-9%
|
(25)
-9%
|
(21)
+17%
|
(21)
+1%
|
(23)
-10%
|
(25)
-10%
|
(30)
-20%
|
(30)
0%
|
(31)
-3%
|
(25)
+18%
|
|